Mildly to moderately ill COVID-19 adult outpatients given a combination of the monoclonal antibodies bamlanivimab and etesevimab early in the disease had significantly lower viral loads at day 11 than those who received a placebo, but a similar effect was not seen in those given bamlanivimab alone, a study published today in JAMA finds.

Bamlanivimab manufacturer Eli Lilly sponsored the double-blind phase 2/3 BLAZE-1 clinical trial, which involved 533 COVID-19 patients at 49 US medical centers. The goal was to assess the antispike neutralizing antibodies’ effects on viral loads of SARS-CoV-2, the virus that causes COVID-19, at 11 days and clinical outcomes at 29 days.

Patients who received either bamlanivimab alone or a placebo were enrolled from Jun 17 to Aug 21, 2020, while those given the bamlanivimab and etesevimab combination or placebo were enrolled from Aug 22 to Sep 3, 2020.

Participants were randomly assigned to receive single infusions of 700, 2,800, or 7,000 milligrams (mg) of bamlanivimab, a combination of 2,800 mg each of bamlanivimab and etesevimab, or placebo.

Fewer hospitalizations, ED admissionsPixabay

Read more at CIDRAP…